期刊文献+

美常安联合得舒特治疗腹泻型肠易激综合征的疗效观察 被引量:9

Efficacy of Medilac-s on Diarrhea-Dominant Irritable Bowel Syndrome
原文传递
导出
摘要 目的探讨美肠安治疗腹泻型肠易激综合征的疗效。方法将60例患者随机分为2组,A组30例,口服得舒特50 mg,每天3次。B组30例,口服美常安500 mg,每天3次,得舒特50 mg,每天3次,疗程4周。观察大便性状评分,腹部综合症状等级评分和疗效评价。结果治疗4周后,两组Bristol评分均较治疗前明显提高,腹部症状评分较治疗前都有明显下降,B组改善更明显。两组之间的治疗效果比较有明显差异,B组疗效更好。结论美肠安治疗腹泻型肠易激综合征安全有效。 Objective To evaluate the clinical efficacy of pinaverium bromid alone or combined with medilac-s in relieveng symptoms in patients with diarrhea-dominart irritable bowel syndrome(IBS-D). Methods 60 patients diagnosed as IBS- D according to the Rome Ⅲ criteria by a simple stool description were randomly divided into two groups. Group A(30 patients) received only pinaverium bromid alone (50 mg rid). Group B (30 patients)received pinaverium bromide combined with medilac-s (500 mg tid). Main outcomes assessment included the days of diarrhea, abdominal pain relief, the Bristol stool form scale, the symptomatic scores and curative effect at the end of 4 weeks. Results 4 weeks later, the Bristol stool from scale, the symptomatic score significantly improved in both groups comparing with baseline. In group B improvement was better than group A. There was significant difference of efficiency between group A and group B. Conclusion Medilac-s is an effective and safe agent for treatment of IBS-D.
出处 《临床消化病杂志》 2009年第1期25-27,共3页 Chinese Journal of Clinical Gastroenterology
关键词 腹泻型肠易激综合征 微生态制剂 得舒特 Dian'hea-dominant irritable bowel syndrome Medilac-s Diectel
  • 相关文献

参考文献10

二级参考文献54

共引文献794

同被引文献244

引证文献9

二级引证文献110

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部